Sandoz Canada Inc. launches PrTOBRAMYCIN INHALATION SOLUTION, a generic version of PrTOBI* indicated for pulmonary infections in cystic fibrosis patients
Boucherville, QC, March 30, 2016 – Sandoz Canada Inc. announced the launch of PrTOBRAMYCIN INHALATION SOLUTION, an authorized generic version of PrTOBI* , currently marketed by Novartis Pharmaceuticals Canada Inc. PrTOBRAMYCIN INHALATION SOLUTION, a respiratory antibiotic, is indicated for the management of cystic fibrosis patients with chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infections.
